Skip to content

Trial Summary

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Acronym:

IMCgp100-202

ACTRN/NCT /ethics:

NCT03070392

Scientific title:

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Sponsor / Cooperative group:

Immunocore

Summary:

A phase II randomized, open-label, multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.

Trial & patient characteristics

Cancer TypeMelanoma/Skin
Trial TypeTreatment
PhasePhase II
Age Range18+ years
SexBoth
Tumour StreamUveal Melanoma
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2017-10-16
Anticipated End Datetbc

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting